Food and Drug Administration Backs Longer-Lasting Drug for Macular Degeneration
Written By: BrightFocus Editorial Staff
The following statement was issued by Stacy Pagos Haller, BrightFocus President and CEO:
“The FDA approval of faricimab, to be marketed as Vabysmo™, is an important step forward for vision research, giving new hope for the millions at risk of losing their sight to age-related macular degeneration (AMD).
Vabysmo can improve the quality of life for those living with the neovascular (“wet”) form of AMD and diabetic macular edema, extending the time between treatments to up to four months. A key component of Vabysmo is rooted in the discoveries from pivotal, early-stage research supported by BrightFocus.
The FDA’s approval powerfully affirms the great progress scientists are making toward saving our sight. My deepest thanks to the many researchers and clinical trial volunteers who helped make this breakthrough possible.”
For more information on Vabysmo, go to www.gene.com or 866/422-2377
BrightFocus Foundation is a premier global nonprofit funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. Through its flagship research programs — Alzheimer’s Disease Research, Macular Degeneration Research, and National Glaucoma Research— the Foundation has awarded nearly $300 million in groundbreaking research funding over the past 51 years and shares the latest research findings, expert information, and resources to empower the millions impacted by these devastating diseases. Learn more at brightfocus.org.
Disclaimer: The information provided here is a public service of BrightFocus Foundation and is not intended to constitute medical advice. Please consult your physician for personalized medical, dietary, and/or exercise advice. Any medications or supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical products or therapies.
BrightFocus proudly supports over 200 cutting-edge research grants, fueling the global fight against Alzheimer’s disease, macular degeneration, and glaucoma.
BrightFocus Foundation’s 2024 annual report highlights groundbreaking research and public awareness efforts over the last year to defeat Alzheimer’s disease, macular degeneration, and glaucoma.
Global brain and vision research nonprofit BrightFocus Foundation has appointed three industry leaders to its board of directors.
BrightFocus Foundation hosted its inaugural Concert for Cures on Wednesday, June 26, at City Winery in Nashville.
